GP
XLRN

GLG Partners’s Acceleron Pharma XLRN Stock Holding History

GLG Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,973
Closed -$265K – 527
2015
Q1 		$265K Sell
6,973
-35,791
-84% -$1.42M 0.01% 358
2014
Q4 		$1.67M Buy
+42,764
New +$1.49M 0.05% 266

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

GLG Partners's XLRN Position: Q2 2015 in Review

GLG Partners sold out of Acceleron Pharma (XLRN) in Q2 2015, closing a stake of 6,973 shares — an estimated $265K sold.

GLG Partners first reported a position in XLRN in Q4 2014 and held it in 2 quarters. The position peaked at $1.67M in Q4 2014. 117 funds tracked by Wall St. Rank hold XLRN as of Q2 2015.

  • GLG Partners reported no remaining Acceleron Pharma position as of Q2 2015 after selling out during the quarter.
  • GLG Partners sold 6,973 Acceleron Pharma shares in Q2 2015, an estimated $265K.
  • GLG Partners first reported a position in Acceleron Pharma in Q4 2014 and held it in 2 quarters.
  • GLG Partners's Acceleron Pharma position peaked at $1.67M in Q4 2014.
  • 117 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2015.

Based on GLG Partners's 13F filing for Q2 2015, filed 14 Aug 2015.